期刊文献+
共找到8篇文章
< 1 >
每页显示 20 50 100
冷抗体溶血综合征输血的临床研究
1
作者 王玉敏 陈琳 《中国误诊学杂志》 CAS 2006年第7期1306-1306,共1页
关键词 贫血 溶血性 自身免疫性/病因 输血
下载PDF
Etiology of chronic pancreatitis:Has it changed in the last decade? 被引量:10
2
作者 Raffaele Pezzilli 《World Journal of Gastroenterology》 SCIE CAS CSCD 2009年第38期4737-4740,共4页
The evidence from recent surveys on chronic pancreatitis carried out around the world shows that alcohol remains the main factor associated with chronic pancreatitis, even if at a frequency lower than that reported pr... The evidence from recent surveys on chronic pancreatitis carried out around the world shows that alcohol remains the main factor associated with chronic pancreatitis, even if at a frequency lower than that reported previously. It has further conf irmed that heavy alcohol consumption and smoking are independent risk factors for chronic pancreatitis. Autoimmune pancreatitis accounts for 2%-4% of all forms of chronic pancreatitis, but this frequency will probably increase over the next few years. The rise in idiopathic chronic pancreatitis, especially in India, represents a black hole in recently published surveys. Despite the progress made so far regarding the possibility of establishing the hereditary forms of chronic pancreatitis and the recognition of autoimmune pancreatitis, it is possible that we are more inaccurate today than in the past in identifying the factors associated with chronic pancreatitis in our patients. 展开更多
关键词 Cohort studies Combined modality therapy Data collection GENETICS PANCREATITIS ALCOHOLIC Population
下载PDF
Nodular regenerative hyperplasia:Evolving concepts on underdiagnosed cause of portal hypertension 被引量:20
3
作者 Marek Hartleb Krzysztof Gutkowski Piotr Milkiewicz 《World Journal of Gastroenterology》 SCIE CAS CSCD 2011年第11期1400-1409,共10页
Nodular regenerative hyperplasia(NRH)is a rare liver condition characterized by a widespread benign transformation of the hepatic parenchyma into small regenerative nodules.NRH may lead to the development of non-cirrh... Nodular regenerative hyperplasia(NRH)is a rare liver condition characterized by a widespread benign transformation of the hepatic parenchyma into small regenerative nodules.NRH may lead to the development of non-cirrhotic portal hypertension.There are no published systematic population studies on NRH and our current knowledge is limited to case reports and case series.NRH may develop via autoimmune,hematological,infectious,neoplastic,or drug-related causes.The disease is usually asymptomatic,slowly or nonprogressive unless complications of portal hypertension develop.Accurate diagnosis is made by histopathology,which demonstrates diffuse micronodular transformation without fibrous septa.Lack of perinuclear collagen tissue distinguishes NRH from typical regenerative nodules in the cirrhotic liver.While the initial treatment is to address the underlying disease,ultimately the therapy is directed to the management of portal hypertension.The prognosis of NRH depends on both the severity of the underlying illness and the prevention of secondary complications of portal hypertension.In this review we detail the epidemiology,pathogenesis,diagnosis,management,and prognosis of NRH. 展开更多
关键词 Nodular regenerative hyperplasia Portal hypertension COMORBIDITIES
下载PDF
Molecular mechMolecular mechanism of glucocorticoid resistance in inflammatory bowel disease 被引量:14
4
作者 Sara De Iudicibus Raffaella Franca +2 位作者 Stefano Martelossi Alessandro Ventura Giuliana Decorti 《World Journal of Gastroenterology》 SCIE CAS CSCD 2011年第9期1095-1108,共14页
Natural and synthetic glucocorticoids (GCs) are widely employed in a number of inflammatory, autoimmune and neoplastic diseases, and, despite the introduction of novel therapies, remain the first-line treatment for in... Natural and synthetic glucocorticoids (GCs) are widely employed in a number of inflammatory, autoimmune and neoplastic diseases, and, despite the introduction of novel therapies, remain the first-line treatment for inducing remission in moderate to severe active Crohn’s disease and ulcerative colitis. Despite their extensive therapeutic use and the proven effectiveness, considerable clinical evidence of wide inter-individual differences in GC efficacy among patients has been reported, in particular when these agents are used in inflammatory diseases. In recent years, a detailed knowledge of the GC mechanism of action and of the genetic variants affecting GC activity at the molecular level has arisen from several studies. GCs interact with their cytoplasmic receptor, and are able to repress inflammatory gene expression through several distinct mechanisms. The glucocorticoid receptor (GR) is therefore crucial for the effects of these agents: mutations in the GR gene (NR3C1, nuclear receptor subfamily 3, group C, member 1) are the primary cause of a rare, inherited form of GC resistance; in addition, several polymorphisms of this gene have been described and associated with GC response and toxicity.However, the GR is not self-standing in the cell and the receptor-mediated functions are the result of a complex interplay of GR and many other cellular partners. The latter comprise several chaperonins of the large cooperative hetero-oligomeric complex that binds the hormonefree GR in the cytosol, and several factors involved in the transcriptional machinery and chromatin remodeling, that are critical for the hormonal control of target genes transcription in the nucleus. Furthermore, variants in the principal effectors of GCs (e.g. cytokines and their regulators) have also to be taken into account for a comprehensive evaluation of the variability in GC response. Polymorphisms in genes involved in the transport and/or metabolism of these hormones have also been suggested as other possible candidates of interest that could play a role in the observed inter-individual differences in efficacy and toxicity. The best-characterized example is the drug efflux pump P-glycoprotein, a membrane transporter that extrudes GCs from cells, thereby lowering their intracellular concentration. This protein is encoded by the ABCB1/ MDR1 gene; this gene presents different known polymorphic sites that can influence its expression and function. This editorial reviews the current knowledge on this topic and underlines the role of genetics in predicting GC clinical response. The ambitious goal of pharmacogenomic studies is to adapt therapies to a patient’s specific genetic background, thus improving on efficacy and safety rates. 展开更多
关键词 GLUCOCORTICOIDS Inflammatory bowel disease PHARMACOGENOMICS
下载PDF
Prevention of Autoimmune Diabetes by Pentoxifylline is Associated with Target Tissue Modulation of Cytokines and the Expression of Fas-FasL
5
作者 刘云峰 章毅 +2 位作者 任如枫 孙辽 张志利 《Journal of Microbiology and Immunology》 2004年第1期56-61,共6页
The effect of Pentoxifylline (PTX) on type 1 diabetes was investigated by means of the studies on the expressions of cytokine mRNA in pancreas and the Fas-FasL on islet cells of NOD mice. NOD mice were treated with PT... The effect of Pentoxifylline (PTX) on type 1 diabetes was investigated by means of the studies on the expressions of cytokine mRNA in pancreas and the Fas-FasL on islet cells of NOD mice. NOD mice were treated with PTX from 4-6?wk, and then from 8-12?wk. After treatment, it was found that the incidence of diabetes in NOD mice at ages of 30?wk was reduced to 25% in group of mice treated with PTX, in comparison to 73.3% in case of mice injected with PBS, and the degree of insulitis in the PTX treated mice was lower than that of the PBS injected mice. RT-PCR analysis revealed down-regulatory effect on the expressions of IFN-γ and TNF-α mRNA in PTX treated mice, but there was no any effect on the expression of IL-10. As to the expression of Fas, there was marked decrease in the mean cytoplasmic integral optical density (IOD) in PTX treated mice, but there was little difference between PTX and PBS groups in the expression of FasL. These results indicated that PTX could prevent the development of diabetes in NOD mice, which might be related to the regulation of Th1/Th2 imbalance and the decreased expression of Fas in islet cells. 展开更多
关键词 PENTOXIFYLLINE DIABETES CYTOKINE FAS-FASL
下载PDF
从病例看“自身免疫(相关)性癫痫”在临床诊治中的挑战
6
作者 金丽日 吴立文 《癫痫杂志》 2022年第4期287-292,共6页
通过回顾性分析3例代表性临床病例的诊断、治疗及后期随访资料,以揭示目前有关“自身免疫(相关)性癫痫”在诊断和治疗方面存在的挑战和问题,并通过文献复习来探讨合理的应对策略。3例患者中,2例因反复癫痫发作就诊,在临床未明显提示免... 通过回顾性分析3例代表性临床病例的诊断、治疗及后期随访资料,以揭示目前有关“自身免疫(相关)性癫痫”在诊断和治疗方面存在的挑战和问题,并通过文献复习来探讨合理的应对策略。3例患者中,2例因反复癫痫发作就诊,在临床未明显提示免疫病因的情况下,多次送检相关抗体或启动免疫治疗。另1例患者临床除了癫痫发作,还有其他脑病表现,结合病史和影像所见高度提示免疫病因,最终经抗体检测阳性结果证实。3例患者的诊治经过提示,目前对“自身免疫(相关)性癫痫”诊断和治疗存在一定程度“过度化”情况。“自身免疫”和“癫痫”的关系较为复杂。自身免疫性脑炎中的癫痫发作和慢性自身免疫(相关)性癫痫之间的界限仍不清晰,缺乏可用于实际操作的标准(如生物标记物)是造成后者混乱临床诊疗现状的重要原因。现阶段,理清诸如“急性症状性发作”和“癫痫”等基本概念,仔细全面评估患者,尽早识别出自身免疫性脑炎中已经确定的、具有一定表型特征的综合征,以及使用可指导临床送检抗体或启动免疫治疗的相关评测量表,可帮助临床医生更加合理、有效地诊疗。 展开更多
关键词 癫痫发作 癫痫 自身免疫性病因 免疫治疗
原文传递
自身免疫起源的迟发性癫痫流行率和临床结局:一项前瞻性观察性人群队列研究
7
作者 Felix von Podewils Marie Suesse +12 位作者 Julia Geithner 张颖颖 童馨 慕洁 Gaida B Wang ZI Lange J Dressel A Grothe M Kessler C Langner S Runge U Bien CG 《癫痫杂志》 2018年第3期242-248,共7页
众所周知,随着年龄增长新发癫痫的发病率增加。通常,这些患者的病因难以明确。研究调查了有非诱导性迟发性癫痫发作且不合并肿瘤(可能患有副肿瘤性脑炎)患者的潜在自身免疫反应情况。在4.75年内前瞻性连续纳入了66例患者(至少有一次癫... 众所周知,随着年龄增长新发癫痫的发病率增加。通常,这些患者的病因难以明确。研究调查了有非诱导性迟发性癫痫发作且不合并肿瘤(可能患有副肿瘤性脑炎)患者的潜在自身免疫反应情况。在4.75年内前瞻性连续纳入了66例患者(至少有一次癫痫或癫痫发作,病程≤6个月,36例女性,年龄≥55岁)。检测所有患者的血清、脑脊液抗体和神经细胞表面、细胞内抗原。45例患者(68%)进行了核磁共振(MRI)检查。对于抗体阳性的患者随访时间至少6个月。2例患者血清、脑脊液中抗接触蛋白相关性蛋白样-2(Contactin associated protein-like 2,CASPR2)抗体滴度高,符合明确边缘性脑炎的诊断标准。另外2例患者MRI显示双侧脑颞区炎性异常,尽管血清、脑脊液抗体阴性,也符合明确边缘性脑炎的诊断标准。这4例患者年龄55~70岁之间,均接受了抗免疫治疗和(或)抗癫痫治疗之后变成癫痫再无发作。该研究发现提示自身免疫应该被认为是迟发型癫痫患者的一个重要病因。对于这些患者,神经元抗体检测和大脑MRI可能是有价值的检查手段。 展开更多
关键词 自身免疫性病因 迟发型癫痫 神经元抗体
原文传递
支原体肺炎造成血常规冷凝集一例 被引量:1
8
作者 张金彪 代荣琴 《中国医师杂志》 CAS 2012年第1期4-4,共1页
肺炎,支原体/并发症;贫血,溶血性,自身免患者,28岁,因发热、咳嗽于2011年5月10日就诊于当地医院,血常规检查均正常。考虑呼吸道感染,后予头孢类抗生素静脉点滴治疗,3d后症状无明显好转,来本院呼吸内科住院治疗。肺部CT示:... 肺炎,支原体/并发症;贫血,溶血性,自身免患者,28岁,因发热、咳嗽于2011年5月10日就诊于当地医院,血常规检查均正常。考虑呼吸道感染,后予头孢类抗生素静脉点滴治疗,3d后症状无明显好转,来本院呼吸内科住院治疗。肺部CT示:肺炎。体温在37.9-38.5℃之间波动。 展开更多
关键词 肺炎 支原体/并发症 贫血 溶血性 自身免疫性/病因 病例报告
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部